Abbott Richard David 4

What Happened

• Richard D. Abbott, President of Co-Diagnostics, reported the vesting/conversion of 1,890 restricted stock units into common shares (acquired at $0.00) on May 23, 2026. To satisfy tax-withholding obligations, 680 of those shares were sold back to the issuer at $5.07 per share for proceeds of $3,448. The net shares retained from this vesting event were 1,210 (1,890 acquired minus 680 sold).

Key Details

• Transaction date: May 23, 2026.
• Conversions/awards: 1,890 shares acquired at $0.00 (transaction code A/M — RSU conversion/exercise).
• Sale to issuer: 680 shares disposed at $5.07 for $3,448 (transaction code D). This sale is a "sell-to-cover" to satisfy tax withholding (see footnote F2).
• Footnote F1: These shares are part of prior RSU awards (4,000 RSUs awarded 4/26/2024 and 7,334 RSUs awarded 8/13/2025) that vest in scheduled installments.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing: Form 4 filed 2026-05-27 reporting the 5/23/2026 transactions; no indication the filing was late.

Context

• This was a routine RSU vesting and a sell-to-cover tax withholding, not an open-market discretionary sale. The exercise/conversion of RSUs followed by a partial automatic sale to cover taxes is common and typically reflects tax mechanics rather than a direct insider view on valuation.